Results 181 to 190 of about 48,006 (264)

A precision gene-engineered B cell medicine producing sustained levels of active factor IX for hemophilia B therapy. [PDF]

Mol Ther
Liu H, Singh S, Mullen TJ, Bullock C, Keegan S, Patterson T, Thakur S, Lundberg A, Shenker S, Couto R, Yadav C, Dastagir S, Li L, Bainter W, Liberzon E, Malloy CR, Lazzarotto CR, Ohsumi TK, Chilakala S, Chen HM, Kshirsagar R, Hohmann AF, Arlauckas SP, Lazorchak A, Scull C, Morgan RA.   +25 more
europepmc   +1 more source

Completion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years. [PDF]

Blood Adv
von Drygalski A, Gomez E, Giermasz A, Castaman G, Key NS, Lattimore SU, Leebeek FWG, Miesbach WA, Recht M, Monahan PE, Le Quellec S, Pipe SW.   +11 more
europepmc   +1 more source

Assessing factor consumption and bleeding outcomes of prophylaxis with 3 commonly prescribed factor IX products for hemophilia B: A retrospective patient medical record analysis in the United States. [PDF]

J Manag Care Spec Pharm
Escobar M, Yan S, Yang Y, Drelich D, Zhang X, Kayode G, Jabati M, Simpson M.   +7 more
europepmc   +1 more source

Identification of Novel <i>F9</i> Gene Variants in 143 Vietnamese Patients with Hemophilia B. [PDF]

J Blood Med
Bach KQ, Duong CQ, Vu HTB, Nguyen BTN, Nguyen TT, Nguyen MT, Li R, Hutchison W, Esaq FS, Tran H, Nguyen TH.   +10 more
europepmc   +1 more source

The Indian Experience With Nonacog Beta Pegol for the Treatment of Hemophilia B in Children and Adolescents: A Safety and Efficacy Evaluation. [PDF]

Cureus
Patel N, Pandav G, Thanvi R, Solanki P, Shah D, Katara A.   +5 more
europepmc   +1 more source

Total Hip Arthroplasty for Avascular Necrosis in a Patient With Hemophilia B. [PDF]

Arthroplast Today
Dandamudi S, Tseng J, Ratz J, Boggio L, Levine BR.   +4 more
europepmc   +1 more source

Trenonacog alfa safety, efficacy, and pharmacokinetics in previously treated pediatric hemophilia B. [PDF]

Res Pract Thromb Haemost
Vilchevska K, Balkan C, Turea V, Gurtchumelia D, Loureiro Prezotti AN, Oliveira de Oliveira LC, Leon J, Fosdal M, Mahlangu J.   +8 more
europepmc   +1 more source

Erratum to "Relationship between Dose, Factor IX Activity Levels and Bleeding Probability for rIX-FP Prophylaxis in Hemophilia B: A Repeated Time-to-Event Analysis". [PDF]

Clin Pharmacol Ther
europepmc   +1 more source